Status:
UNKNOWN
Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Liver Fibrosis
Cirrhosis
Eligibility:
All Genders
18-70 years
Brief Summary
This study is to establish a noninvasive diagnostic platform based on hemodynamic information for the assessment of liver fibrosis, liver cirrhosis and portal hypertension.
Detailed Description
As the hemodynamics of liver vessels depend on the liver tissue mechanics, we hypothesize that the hemodynamics measurements of the liver are strongly correlated with the stages of liver fibrosis and ...
Eligibility Criteria
Inclusion
- Inpatients who undergo liver biopsy or hepatic venous pressure gradient test
Exclusion
- decompensated liver diseases (including ascites, variceal bleeding or hepatic encephalopathy);
- alpha-fetoprotein \>100 ng/ml or serum creatinine \>1.5 × upper limit of normal (ULN);
- any malignant tumor;
- any complications of severe heart, lung, kidney, brain, blood diseases or other important systematic diseases;
- severe neurological or psychological disease;
- pregnant or lactating women.
Key Trial Info
Start Date :
October 9 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03277651
Start Date
October 9 2017
End Date
December 31 2020
Last Update
January 10 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China, 200032